Clinical trials: Immunoglobulin
Breast Cancer, Non-small Cell Lung Carcinoma
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
- Trial name
- NCT04042701
- Testing
- Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
- Where
- 30 sites in United States, France and 2 more
- Volunteers
- 115 people
- Sponsor
- Daiichi Sankyo
NK/T Cell Lymphoma
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma
To observe the safety, tolerability and clinical effects of PD-1 Antibody, Chidamide, Lenalidomide and Etoposide in Relapsed or Refractory NK/T cell Lymphoma.
- Trial name
- NCT04038411
- Testing
- PD-1 Antibody, chidamide, lenalidomide and etoposide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Mingzhi Zhang
Leukemia, Lymphocytic, Chronic
A Safety Study in Patients With Chronic Lymphocytic Leukemia
This is an open-label, dose-escalation study to determine the tolerability, safety profile, and antitumor activity of SGN-40 in patients with CLL.
- Trial name
- NCT00283101
- Testing
- SGN-40 (anti-huCD40 mAb)
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Seagen Inc.
Advanced Hepatocellular Carcinoma
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
- Trial name
- SIERRA (NCT05883644)
- Testing
- Durvalumab, Tremelimumab
- Where
- 40 sites in United States, France and 8 more
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
RSV Infection
The EMBRACE Study: Enflonsia Monoclonal in Babies - RSV Antibody Concentration Evaluation
Clesrovimab is an FDA-approved antibody drug recommended for infants younger than 8 months who are entering their first respiratory syncytial virus (RSV) season and whose mothers did not receive an RSV vaccine during pregnancy.
- Trial name
- NCT07824167
- Testing
- Clesrovimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University
HER2-expressing Cancers
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage (RD) of ZW49, the investigational agent under study, and to assess the safety…
- Trial name
- NCT03821233
- Testing
- ZW49
- Where
- 16 sites in United States, Australia and 2 more
- Volunteers
- 112 people
- Sponsor
- Zymeworks BC Inc.
Dermatomyositis
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis
This study will evaluate the safety and effectiveness of the experimental drug h5G1.1-mAb in treating patients with dermatomyositis.
- Trial name
- NCT00005571
- Testing
- h5G1.1-mAb
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Passive Transmission of Maternal and Infant Antibodies
Passive Transmission of COVID-19 Antibody From Mother to Infant
At present, there is no relevant research focusing on children's acquisition of novel coronavirus antibodies through maternal passive transmission.
- Trial name
- NCT05851911
- Testing
- sars-cov-2 vaccine or infection
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Chongqing Medical University
Pancreatic Cancer
A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer.
- Trial name
- NCT01472198
- Testing
- Simtuzumab, Gemcitabine
- Where
- 57 sites in United States, Russia
- Volunteers
- 250 people
- Sponsor
- Gilead Sciences
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants
This study will assess both the antibody persistence of the investigational vaccine and the immune response and safety of a booster dose of PENTAXIM™ vaccine in 18 months-old toddlers who participated in an earlier study in order…
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT00303316
- Testing
- DTaP-IPV//PRP~T combined vaccine
- Where
- Argentina
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Sanofi
Systemic Lupus Erythematosus
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
This is a long-term continuation study to provide continuing treatment to subjects with SLE.
- Trial name
- NCT00712933
- Testing
- belimumab
- Where
- 110 sites in Argentina, Austria and 26 more
- Volunteers
- 738 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Adult T-cell Leukemia-Lymphoma
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).
- Trial name
- NCT01626664
- Testing
- KW-0761, Pralatrexate, gemcitabine plus oxaliplatin
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 71 people
- Sponsor
- Kyowa Kirin, Inc.
Microbiome, Immune Function
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
The purpose of this study was to analyze the relationship between the microbial community, host immunity and the presence or absence of concurrent rapidly progressive interstitial lung disease patients with anti-MDA5 antibody…
- Conditions
- Microbiome, Immune Function, Anti-MDA5 Antibody Positive Dermatomyositis
- Trial name
- NCT06203249
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chinese PLA General Hospital
Osteoarthritis
Tanezumab In Osteoarthritis Of The Hip Or Knee
The purpose of the study is to test the efficacy and safety of 2 doses of tanezumab compared to oxycodone CR and placebo in patients with osteoarthritis
- Trial name
- NCT00985621
- Testing
- tanezumab 10 mg, tanezumab 5 mg, oxycodone
- Where
- 112 sites in United States, Austria and 5 more
- Volunteers
- 614 people
- Sponsor
- Pfizer
SARS CoV 2 Infection, SARS CoV 2 Vaccination
COVID-19 Transmission and Morbidity in Malawi
SARS-CoV-2 transmission was expected to have a devastating impact in sub-Saharan African countries. Instead, morbidity and mortality rates in nearly the whole region are an order of magnitude lower than in Europe and the…
- Trial name
- COVID-TMM (NCT05973084)
- Where
- 2 sites in United States, Malawi
- Volunteers
- 1,500 people
- Sponsor
- Boston University
Multiple Myeloma Refractory, Relapsed Multiple Myeloma
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma.
- Trial name
- CHUQUL_HO001 (NCT07094048)
- Testing
- Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- CHU de Quebec-Universite Laval
Head and Neck Cancer
Anti-OX40 Antibody in Head and Neck Cancer Patients
The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.
- Trial name
- NCT02274155
- Testing
- Anti-OX40 antibody administration, Surgical Resection
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Providence Health & Services
Viremia
Yellow Fever Virus Vaccine and Immune Globulin Study
The purpose of this study is to determine whether immune globulin can limit the amount of yellow fever vaccine virus present in the blood after vaccination without compromising the immunity associated with the yellow fever…
- Trial name
- NCT00254826
- Testing
- YF-VAX® plus saline, 17D YF Vaccine plus Ig,
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Emory University
Colorectal Cancer
A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
This Phase II, multicenter, double-blind, randomized, active-controlled trial is designed to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) when administered at a dose of 5 mg/kg every 2 weeks in combination with 5 FU…
- Trial name
- NCT00109226
- Testing
- Avastin (Bevacizumab)
- Sponsor
- Genentech, Inc.
COVID19
Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients
Preparation of safe purified hyper immunoglobulins containing anti-Corona VS2 immunoglobulins from plasma collected from COVID19 convalescent patients to be used to: 1.
- Trial name
- NCT04383548
- Testing
- hyper immunoglobulins containing anti-Corona VS2 immunoglobulin
- Volunteers
- 100 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.